PTHS

Insider Trades

Name	Value	Action	Price	Current Price
Friedberg Ezra MDirector $400k40k shares BuyJul 1, 2025 $10.00 --
Friedberg Ezra MDirector $56k2k shares SellNov 25, 2025 $28.01 --
Friedberg Ezra MDirector $291 shares SellNov 25, 2025 $28.50 --
Friedberg Ezra MDirector $56k2k shares SellNov 25, 2025 $28.14 --
Friedberg Ezra MDirector $168k6k shares SellNov 25, 2025 $28.00 --
Greenleaf PeterDirector $8.1k377 shares SellApr 2, 2026 $21.36 --

News

globenewswire.comPelthos Therapeutics to Participate in 2026 Jefferies Global Healthcare Conferenceglobenewswire.comMay 28

marketbeat.comPelthos Therapeutics Q1 Earnings Call Highlightsmarketbeat.comMay 15

seekingalpha.comPelthos Therapeutics Inc. (PTHS) Q1 2026 Earnings Call Transcriptseekingalpha.comMay 14

zacks.comPelthos Therapeutics Inc. (PTHS) Reports Q1 Loss, Beats Revenue Estimateszacks.comMay 14

globenewswire.comPelthos Therapeutics Announces First Quarter 2026 Financial Resultsglobenewswire.comMay 14

Trade PTHS

About Pelthos Therapeutics Inc.

Pelthos Therapeutics Inc. operates as a biopharmaceutical enterprise dedicated to developing and commercializing innovative medical treatments that address significant, unmet patient needs. Its primary offerings include ZELSUVMI, a medication specifically indicated for the treatment of molluscum contagiosum in individuals aged one year and older. Furthermore, the company leverages NITRICIL, an exclusive technological platform grounded in nitric oxide research. Established in 2002, this Durham, North Carolina-based firm was previously known as Channel Therapeutics Corporation, before rebranding to Pelthos Therapeutics Inc. in July 2025.

CEO: Scott Plesha
IPO Date: Jul 2, 2025

Market Data

Open: $27.50
High: $29.00
Low: $27.26
Volume: 34.4K
Avg Volume: 17.6K
52W High: $54.29
52W Low: $11.20

Valuation

Market Cap: $19M
Enterprise Value: $40M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-23M
Revenue: $17M
Net Income: $-43M
Cash: $18M
Debt: $35M

Events

EarningsAug 12

EPS est. -2.9475